CEACAM7, CEA cell adhesion molecule 7, 1087

N. diseases: 202; N. variants: 0
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Univariate logistic regression analysis showed that CEA (OR 1.056, 95% CI 1.007-1.107, p = 0.02) was the only preoperative predictor for occult metastases. 31186205 2019
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE A decreased overall survival was significantly associated with peritoneal involvement (HR 1.944; p = 0.003), ascites (HR 2.055; p = 0.034), synchronous presentation (HR 1.679; p = 0.034) and increased serum CEA levels (HR 1.380; p = 0.010), but not with age > 50 (HR 0.946; p = 0.743), menopausal status (HR 1.565; p = 0.204), gastric origin (HR 1.600; p = 0.201), size > 5 cm (HR 1.292; p = 0.119), size > 10 cm (HR 0.925; p = 0.714), bilateral ovarian involvement (HR 1.113; p = 0.347), non-peritoneal extaovarian metastases (HR 1.648; p = 0.237), liver metastases (HR 1.118, p = 0.555), predominant signet ring cell morphology (HR 1.322; p = 0.208) and levels of CA125 (HR 0.933; p = 0.828) and CA19.9 (HR 0.996; p = 0.992). 31542818 2019
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE High platelet count (H-PC) was found in 32%, and it was associated with a higher rate of palliative surgery (p < 0.001), extra-hepatic metastases (p < 0.001), bilobar liver disease (p = 0.007), presence of more than three metastases (p = 0.005), biggest metastasis larger than 5 cm (p < 0.001), and CEA level higher than 200 ng/mL (p = 0.035). 30937817 2019
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Several pretreatment factors, including lower carcinoembryonic antigen (CEA; ≤20 ng/mL), lower aspartate transaminase (AST; ≤40 IU/L), neutrophil-lymphocyte ratio (NLR) <5, and absence of extrahepatic disease at baseline were associated with significantly improved OS after RE, compared with high CEA (>20 ng/mL), high AST (>40 IU/L), NLR ≥5, and extrahepatic metastases (P values of <.001, <.001, .0001, and .04, respectively). 29754852 2018
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE CEA and CA125 were associated with tumor metastasis and therapeutic response. 28267695 2017
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE Furthermore, deguelin-treated tumors showed decreased the tumor metastasis related genes such as CD44, MMP2 and MMP9 at protein and mRNA levels and the content of CEA, SCC, NSE, CYFAR21-1. 26884827 2015
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE Postoperative follow-up found that all patients with high levels of CEA mRNA and serum CEA and the related proteins had liver, lung, pelvis, or other distant metastases. 24783267 2014
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE In patients with distant metastases and ascites the levels of CEA, CA19-9, and CA24-2 were higher than in patients without these conditions (p=0.003, p=0.001, p=0.001, p=0.016, p= 0.011, and p=0.030, respectively). 23787496 2013
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE To determine whether 1 of 2 vaccines based on dendritic cells (DCs) and poxvectors encoding CEA (carcinoembryonic antigen) and MUC1 (PANVAC) would lengthen survival in patients with resected metastases of colorectal cancer (CRC). 23657083 2013
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE CEA levels of HNPCC tumors increased significantly under occurrence of metastases with mean values of 170.3 +/- 343 (p < 0.02). 16122885 2005
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE We, in the present study, constructed a self-replicable adenovirus in which E1A is driven by a CEA promoter and E1B-55K is deleted from the E1B region (AdCEAp/Rep) and examined its effects on multiple metastases of a human colon cancer cell in a mouse xenograft model. 15564136 2004
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Endometrial carcinomas and their metastases were generally positive for ER (86%), PR (93%) and VIM (100%) but rarely positive for CEA (14%) and HPV (0%). 15010819 2004
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE These results show that both mammaglobin RT-PCR and CEA RT-PCR are useful tools for the detection of breast cancer metastases in axillary lymph nodes. 11592097 2001
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 Biomarker group BEFREE Hitherto anti-CEA monoclonal antibodies (MAbs), normally of mouse origin, have been used primarily for clinical diagnosis of colorectal cancer, either as a tumor marker in serum to monitor tumor recurrence, or latterly as a means to localize in vivo CEA-bearing tumors, and metastases in patients. 1431347 1992
CUI: C2939419
Disease: Secondary Neoplasm
Secondary Neoplasm
0.100 AlteredExpression group BEFREE CEA mRNA did not appear to correlate with metastasis because its expression in the primary colon cancers with metastases (Dukes' stage D tumor) was not always increased. 1290028 1992